Regulatory & Legal Archive
28-09-2017 EMA: On the 21 September 2017, the European Commission granted a Marketing Authorisation for Symtuza (darunavir / cobicistat / emtricitabine / tenofovir alafenamide), indicated for HIV Infections. The Marketing Authorization Holder for this medicinal product is Janssen-Cilag International N.V.
26-09-2017 EMA: Update on EMA relocation preparedness.
13-09-2017 EMA: On the 22 August 2017, the European Commission granted a Marketing Authorization for Mavenclad (cladribine), indicated as treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features. The Marketing Authorization Holder for this medicinal product is Merck Serono Europe Limited.
In an unexpected move, just before the end of 2011, ...
Improving expenditure efficiency has been, for a ver...
Your Portal Link to Mass Media Universe.
Valuable Quarterly Romanian Market Analysis.
Ask the analyst
Tailor-made advice for you